NCT01405846View on ClinicalTrials.gov

Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2016

Conditions
Lung CancerHead and Neck Cancer
Interventions
DRUG

Gefitinib

250mg od for 6 months

Trial Locations (1)

CB23 3RE

Papworth Hospital NHS Trust, Papworth Everard

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Noble Organisation

UNKNOWN

lead

Papworth Hospital NHS Foundation Trust

OTHER_GOV